In the pivotal BRUNELLO trial, both doses of remigromig, a Wnt pathway agonist, were noninferior to ranibizumab for diabetic ...
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help ...
Artificial intelligence (AI) could help close gaps in eye care for underserved communities, but only if the tools reach the ...
Access to emergency eye care remains a public health challenge, with gaps that affect patients and communities across the ...
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in ...
Overall, the researchers concluded that GLP-1RAs had a protective association with the development of DME compared with ...
Adults with colorectal cancer (CRC) in states that expanded Medicaid under the Affordable Care Act (ACA) had lower mortality ...
Michael Mina, MD, PhD, explains LIBERTY trial findings on VYD2311 tolerability alone and given with an mRNA COVID-19 vaccine.
At the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, Michael F. Chiang, MD, director of the National Eye ...
The FDA has approved olanzapine extended-release injectable suspension (Weltruza; Teva Pharmaceuticals), a once-monthly ...
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable ...
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results